cas 573762-62-6|| where to buy 5-Amino-3-(trifluoromethyl)picolinonitrile

Nom du produit:5-Amino-3-(trifluoromethyl)picolinonitrile

IUPAC Name:5-amino-3-(trifluoromethyl)pyridine-2-carbonitrile

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM177488-1000g	in stock	ŹĽĽƓ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 573762-62-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:573762-62-6; Formule moléculaire:C7H4F3N3; Point de fusion:-; Code SMILES:N#CC1=NC=C(N)C=C1C(F)(F)F; Densité:

: Numéro de catalogue:CM177488; Poids moléculaire:187.13; Point d'ébullition:; N° Mdl:; Stockage:Keep in dark place, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Apalutamide; Johnson & Johnson announced results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months. ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.